Promoter hypermethylation of tumor-associated genes in head and neck cancer

Journal of Otolaryngology of Japan

Volumn 108, Issue 3, 2005, Pages 207-213

  Okami, Kenji ^a   Sakai, Akihiro ^a   Onuki, Junichi ^a   Hamano, Takahide ^a   Iida, Masahiro ^a   Takahashi, Masahiro ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fhit; p16; RAR ; RASSF1A; Tumor suppressor gene

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA;

ARTICLE; CARCINOGENESIS; CPG ISLAND; DNA METHYLATION; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ONCOGENE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION;

EID: 17044372856     PISSN: 00306622     EISSN: None     Source Type: Journal    
DOI: 10.3950/jibiinkoka.108.207     Document Type: Article

References (34)

1. Okami K, Reed AL, Cairns P, Koch WM, Westra WH, et al: Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 1999; 18: 3541-3545.
2. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, et al: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3633.
3. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, et al: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995; 11: 210-212.
4. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, et al: Inactivation of the p16/CDKN2/MTS1 gene is associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4530.
5. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-167.
6. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al: 5′ CpG island methylation is associated with transcription silencing of the tumor suppressor p16/CDKN 2/MTS1 in human cancers. Nature Med 1995; 1: 686-692.
7. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, et al: Gene promotorhypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000; 60: 892-895.
8. Rosas, SLB, Koch W, da Costa Carvalho MG, Wu L, Califano J, et al: Promoter hypermethylation patterns of p16, 06-methylguanine-DNA- methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001; 61: 939-942.
9. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG island. Pros Natl Acad Sci USA 1996; 93: 9821-9826.
10. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, et al: Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 2002; 8: 131-137.
11. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, et al: Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001; 7: 3135-3138.
12. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, et al: Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst 2000; 92: 1303-1307.
13. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, et al: 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001; 61: 3581-3585.
14. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25: 2532-4.
15. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, et al: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992; 89: 1827-1831.
16. Okami K, Imate Y, Hashimoto Y, Kamada T, Takahashi M: Molecular detection of cancer cells in saliva from oral and pharyngeal cancer patients. Tokai J Exp Clin Med 2002; 27: 85-89.
17. Hasegawa M, Nelson, HH, Peters E, Ringstrom E, Posner M, et al: Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002; 21: 4231-4236.
18. Hayashi K, Yokozaki H, Naka K, Yasui W, Yajin K, et al: Effect of 9-cis-retinoic acid on oral squamous cell carcinoma cell lines. Cancer Lett 2000; 151: 199-208.
19. Yang Q, Mori I, Shan L, Nakamura M, Nakamura Y, et al: Biallelic inactivation of retinoic acid receptor β2 gene by epigenetic change in breast cancer. Am J Pathol 2001; 158: 299-303.
20. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Hansjuerg A, et al: Allele loss and promoter hypermethylation of VHL, RAR-β, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003; 63: 3724-3728.
21. Dammann R, Li C, Yoon JH, Chin PL, Bates S, et al: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21. 3. Nat Genet 2000; 25: 315-319.
22. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, et al: The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004; 6: 129-137.
23. Chang HW, Chan A, Kwong DLW, Wei WI, Sham JST, et al: Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharyngeal carcinoma patient. Int J cancer 2003; 105: 851-855.
24. Lo KW, Kwong J, Hui AB, Chan SY, To KF, et al: High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001; 61: 3877-3881.
25. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, et al: Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 2003; 9: 3635-3640.
26. Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, et al: Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumor suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer 2002; 38: 1585-1592.
27. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, et al: FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996; 93: 9770-9775.
28. Mineta H, Miura K, Takebayashi S, Misawa K, Ueda Y, et al: Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma. Oral Oncol 2003; 39: 56-63.
29. Chang KW, Kao SY, Tzeng RJ, Liu CJ, Cheng AJ, et al: Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J Pathol 2002; 1963: 300-306.
30. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, et al: Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 1998; 58: 3429-3434.
31. Hibi K, Nakayama H, Koike M, Kasai Y, Ito K, et al: Colorectal cancers with both p16 and p14 methylation show invasive characteristics. Jpn J Cancer Res 2002; 93: 883-887.
32. Spafford MF, Koch WM, Reed AL, Califano JA, Xu LH, et al: Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res 2001; 7: 607-612.
33. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, et al: Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999; 91: 332-339.
34. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, et al: Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 2307-2312.